During the 1970s and 1980s, over 30,000 individuals in the UK found themselves infected with HIV and Hepatitis C due to receiving contaminated blood products, marking what has been termed the most significant treatment catastrophe in the history of the National Health Service (NHS). This public health crisis, which will soon be under scrutiny with the impending release of findings from a comprehensive inquiry this May, has spurred victims to push for compensation.

Who were the victims, and how extensive was the impact of this infected blood scandal?

The fallout primarily affected two major groups within the NHS. Firstly, individuals with disorders like haemophilia, characterised by a deficiency in clotting agents, were unwittingly exposed to contaminated Factor VIII and IX products derived from human blood plasma donations.

Shockingly, estimates suggest that approximately 1,250 individuals with these disorders contracted both HIV and hepatitis C, including tragically, 380 children. Around two-thirds later died of AIDS-related illnesses, while some unintentionally transmitted HIV to their partners. Another 2,400 to 5,000 people developed Hepatitis C on its own, which can cause cirrhosis and liver cancer.

Calculating the exact number of those affected by Hepatitis C remains challenging due to its long latency period for symptom manifestation.

Additionally, a second group of patients, including those who underwent medical procedures like childbirth or surgery, also fell victim to infected blood transfusions during the period spanning 1970 to 1991. This group saw an estimated 80 to 100 individuals infected with HIV and roughly 27,000 individuals infected with Hepatitis C. In total, the devastating toll of the scandal claimed approximately 2,900 lives.

How did this tragedy unfold, and what knowledge did authorities know about the risks involved?

In the 1970s, the UK faced a shortfall in blood-clotting treatments, leading to the importation of supplies, notably from the US, where blood was often sourced from high-risk donors such as prison inmates and drug users.

Factor VIII, crucial for individuals with bleeding disorders, was manufactured by pooling plasma from thousands of donors, posing an inherent risk of contamination if any donor carried a virus. Shockingly, routine screening for hepatitis C in UK blood donations wasn’t implemented until 1991, a significant delay considering the virus was identified in laboratories 18 months prior.

By the mid-1970s, warnings were sounded about the elevated risk associated with imported Factor VIII, yet efforts to achieve self-sufficiency in blood products stalled, leading to continued reliance on foreign sources. Also, evidence suggests that viable alternative treatments, like Cryoprecipitate, which carried a lower infection risk, were underutilised. Tragically, even clinical trials of new treatments saw children infected with hepatitis C and HIV without family consent.

The official response to the growing crisis was marred by delays and denials, with the government insisting as late as November 1983 that there was no definitive proof of HIV transmission via blood. It wasn’t until the end of 1985 that heat treatment was implemented to eliminate HIV from Factor VIII products.

When was the inquiry launched, and what will its report entail?

The Infected Blood Inquiry, established in 2017 following extensive advocacy efforts by victims, is set to unveil its comprehensive findings on May 20th. Led by former judge Sir Brian Langstaff, the inquiry, which gathered evidence from 2019 to 2023, necessitated additional time for meticulous preparation due to the severity of the case.

Exact figures are challenging to determine, but it’s estimated that since the inquiry’s inception, approximately 650 individuals infected with contaminated blood products, or their bereaved partners, have passed away. Testimonies heard by the inquiry have been both heartbreaking and revealing, offering insights from survivors, medical professionals, and even former government officials.

What about compensation for the victims?

While interim financial support has been provided by the government, a final compensation package remains unresolved. Following the inquiry’s counsel, interim payments of £100,000 were issued to around 4,000 survivors and certain bereaved partners in late 2022. Sir Brian Langstaff recommended extending interim compensation to affected children and parents, alongside backing a comprehensive compensation scheme, the cost of which is expected to be substantial.

Although the government has acknowledged the moral imperative for compensation, it has refrained from committing until the inquiry’s full report is released. However, recent developments signal progress, with ministers pledging support for legislation mandating a final compensation scheme within three months of its enactment.

How did other affected countries address similar challenges?

The infected blood scandal surpasses borders, with numerous countries dealing with comparable crises. While some nations, like Finland, maintained self-sufficiency in Factor VIII, mitigating HIV infections, others, like the US, witnessed substantial out-of-court settlements from companies responsible for supplying contaminated products. Legal actions against politicians and drug companies for negligence have also unfolded in countries like France and Japan, with the UK possibly facing similar considerations of corporate manslaughter charges.

As the UK awaits the inquiry’s conclusive report, the nation braces for a reckoning with the appalling consequences of this historic healthcare failure, while victims and their families continue their pursuit of justice and restitution.







Back to News + Insights